$4.20
+1.9%OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.
Chief Financial Officer
Compensation
$565,258
Chief Medical Officer
Compensation
$650,371
Chief Scientific Officer
General Counsel & Secretary
President, Chief Executive Officer & Director
Compensation
$741,743
Senior VP of Clinical Operations
Senior Vice President of Computational Drug Discovery
Senior Vice President of DMPK & Clinical Pharmacology
Senior Vice President of Discovery Chemistry
During the last 12 months, insiders have sold $5K worth of OKUR shares, with no buying activity reported.
0
0.00
387
1.61K
-2K
-$2K
0
0.00
389
1.15K
-1K
-$1K
0
0.00
391
1.02K
-1K
-$1K
0
0.00
391
931.00
-931
-$931
No buying activity
Leverone Jason A.
Officer: Chief Financial Officer
$4K
Saccomano Nicholas A
Director, Officer: President And Ceo
$1K
Strong bearish signal with $5K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
2 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Persistent selling pressure: Consistent insider selling with weak buy/sell ratio suggests insiders may be capitalizing on current valuation. Exercise caution and review recent earnings quality and management commentary.
OKUR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 21, 2026 | June 03, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 16, 2025 | May 27, 2025 | 2025 | |
DEF 14A DEF 14A 2023 N/A | April 26, 2023 | June 06, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 22, 2022 | June 01, 2022 | 2022 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.